CERDELGA
Pour la monothérapie chez les patients adultes atteints d’une maladie de Gaucher de type I …
Additional information from the official database
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
84.4 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
100.0 MG | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
111.5 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | FTODK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HBESI |
1214 Vernier